Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.

Publication

Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.

Journal Paper/Review - Jun 15, 2023

Silzle Tobias, Kahlert Christian, Albrich Werner, Nigg Susanne, Demmer-Steingruber Ruth, Driessen Christoph, Fischer Stefanie

Citation

Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. Swiss Med Wkly 2023; 153:40090.

Type

Journal Paper/Review (English)

Journal

Swiss Med Wkly 2023; 153

Publication Date

Jun 15, 2023

Issn Electronic

1424-3997

Pages

40090

Brief description/objective

Currently available messenger ribonucleic acid (mRNA)-based vaccines against coronavirus disease (COVID-19) have been shown to be effective even in highly immunocompromised hosts, including patients with multiple myeloma. However, vaccination failure can be observed in all patient groups.